(S)-9-bromo-5-(carboxymethyl)-6,7-dihydro-1H,5H-pyrido<1,2,3-de>quinoxaline-2,3-dione | 158328-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (S)-9-bromo-5-(carboxymethyl)-6,7-dihydro-1H,5H-pyrido<1,2,3-de>quinoxaline-2,3-dione
• 英文别名: (S)-9-bromo-5-carboxymethyl-6,7-dihydro-1H, 5H-pyrido[1,2,3-de]quinoxaline-2,3-dione；2-[(12S)-7-bromo-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl]acetic acid
• CAS: 158328-19-9
• 化学式: C₁₃H₁₁BrN₂O₄
• 分子量: 339.145
• InChiKey: RDSPPHOSNHTINE-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-tert-butoxycarbonylaminomethyl-2-methoxycarbonylmethylaniline 、 (S)-9-bromo-5-(carboxymethyl)-6,7-dihydro-1H,5H-pyrido<1,2,3-de>quinoxaline-2,3-dione 以to give 8.02 g of the title compound (61%)的产率得到(S)-9-bromo-5-[p-tert-butoxycarbonylaminomethyl-o-(methoxycarbonylmethyl)phenylcarbamoylmethyl]-6,7-dihydro-1H, 5H-pyrido[1,2,3-de]quinoxaline-2,3-dione
  参考文献：
  名称：

  Tricyclic quinoxalinedione derivatives

  摘要：

  一种三环喹喔啉二酮衍生物，其化学式为1：##STR1## 其中X代表氢、烷基、卤素、氰基、三氟甲基或硝基；R.sup.1代表氢、烷基、环烷基或环烷基烷基；G代表--CONR.sup.2--或--NR.sup.2CO--，其中R.sup.2代表氢或烷基；J代表酸性基团或可在体内转化为酸性基团的基团；E代表碱性基团或可在体内转化为碱性基团的基团；Y代表单键、烷基、烯基、取代烷基或Y.sup.1--Q--Y.sup.2，其中Y.sup.1代表单键或烷基，Y.sup.2代表烷基，Q代表从氧或硫选择的杂原子；Z代表烷基，或其药学上可接受的盐，这些化合物是NMDA受体的选择性甘氨酸结合位点拮抗剂。

  公开号：

  US05719152A1
• 作为产物：
  描述：

  methyl (S)-1,2,3,4-tetrahydroquinoline-2-acetate 在 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 titanium(III) chloride 、 nitronium tetrafluoborate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 6.25h， 生成 (S)-9-bromo-5-(carboxymethyl)-6,7-dihydro-1H,5H-pyrido<1,2,3-de>quinoxaline-2,3-dione
  参考文献：
  名称：

  Tricyclic Quinoxalinediones: 5,6-Dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-Dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as Potent Antagonists for the Glycine Binding Site of the NMDA Receptor

  摘要：

  A series of tricyclic quinoxalinediones, 5,6-dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones, were synthesized and was evaluated for their affinity for the glycine binding site of the NMDA receptor using a [H-3]- 5,7-dichlorokynurenic acid binding assay. The six-membered ring-fused tricyclic quinoxalinedione 18g (K-i = 9.9 nM) displayed high affinity for the glycine site. The anilide derivative 20g (K-i = 2.6 nM) was 4-fold more potent than 18g and as potent as L-689,560, one of the most potent glycine antagonists so far prepared. Although the carboxylic acid derivative of the corresponding five-membered ring-fused tricyclic quinoxalinedione 18e (K-i = 7.3 nM) had affinity comparable to that of 18g, the anilide derivative 20e largely decreased in the affinity in contrast to 20g. Enantiomers 23g, 24g, 25g, and 26g were prepared and tested. Only the S enantiomer 25g (K-i = 0.96 nM) retained the affinity among the anilide derivatives, whereas both enantiomers 23g (K-i = 2.3 nM) and 24g (K-i = 9.6 nM) were active among the carboxylic acid derivatives. The origin of the high affinity of carboxylic acid derivatives such as 18e and 18g would be a charge-charge interaction between the anionic carboxylate residues of the compounds and the cationic proton-donor site in the receptor.

  DOI：

  10.1021/jm00049a015

文献信息

• Tricyclic Quinoxalinediones: 5,6-Dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-Dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as Potent Antagonists for the Glycine Binding Site of the NMDA Receptor
  作者：Ryu Nagata、Norihiko Tanno、Toru Kodo、Nobuyuki Ae、Hiroshi Yamaguchi、Tamiki Nishimura、Fujio Antoku、Tohru Tatsuno、Terufumi Kato

  DOI：10.1021/jm00049a015

  日期：1994.11

  A series of tricyclic quinoxalinediones, 5,6-dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones, were synthesized and was evaluated for their affinity for the glycine binding site of the NMDA receptor using a [H-3]- 5,7-dichlorokynurenic acid binding assay. The six-membered ring-fused tricyclic quinoxalinedione 18g (K-i = 9.9 nM) displayed high affinity for the glycine site. The anilide derivative 20g (K-i = 2.6 nM) was 4-fold more potent than 18g and as potent as L-689,560, one of the most potent glycine antagonists so far prepared. Although the carboxylic acid derivative of the corresponding five-membered ring-fused tricyclic quinoxalinedione 18e (K-i = 7.3 nM) had affinity comparable to that of 18g, the anilide derivative 20e largely decreased in the affinity in contrast to 20g. Enantiomers 23g, 24g, 25g, and 26g were prepared and tested. Only the S enantiomer 25g (K-i = 0.96 nM) retained the affinity among the anilide derivatives, whereas both enantiomers 23g (K-i = 2.3 nM) and 24g (K-i = 9.6 nM) were active among the carboxylic acid derivatives. The origin of the high affinity of carboxylic acid derivatives such as 18e and 18g would be a charge-charge interaction between the anionic carboxylate residues of the compounds and the cationic proton-donor site in the receptor.
• Tricyclic quinoxalinedione derivatives
  申请人：Sumitomo Pharmaceuticals Co., Ltd.

  公开号：US05719152A1

  公开（公告）日：1998-02-17

  A tricyclic quinoxalinedione derivative represented by the formula 1: ##STR1## wherein X represents hydrogen, alkyl, halogen, cyano, trifluoromethyl, or nitro; R.sup.1 represents hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl; G represents --CONR.sup.2 -- or --NR.sup.2 CO--, wherein R.sup.2 represents hydrogen or alkyl; J represents an acidic group or a group which is convertible thereto in vivo; E represents an basic group or a group which is convertible thereto in vivo; Y represents a single bond, alkylene, alkenylene, substituted alkylene, or Y.sup.1 --Q--Y.sup.2, wherein Y.sup.1 represents a single bond or alkylene, Y.sup.2 represents alkylene, and Q represents a heteroatom selected from oxygen or sulfur; Z represents alkylene, or a pharmaceutically acceptable salt thereof, these compounds are selective antagonists of glycine binding site of the NMDA receptor.

  一种三环喹诺酮二酮衍生物，其化学式为1：##STR1## 其中X代表氢、烷基、卤素、氰基、三氟甲基或硝基；R.sup.1代表氢、烷基、环烷基或环烷基烷基；G代表--CONR.sup.2--或--NR.sup.2 CO--，其中R.sup.2代表氢或烷基；J代表酸性基团或体内可转化的基团；E代表碱性基团或体内可转化的基团；Y代表单键、烷基、烯基、取代烷基或Y.sup.1--Q--Y.sup.2，其中Y.sup.1代表单键或烷基，Y.sup.2代表烷基，Q代表从氧或硫中选择的杂原子；Z代表烷基，或其药用可接受盐，这些化合物是NMDA受体的甘氨酸结合位点的选择性拮抗剂。